Treatment of allograft rejection with IL-2 receptor-specific cyt

Details Treatment of allograft rejection with IL-2 receptor-specific cyt Treatment of allograft rejection with IL-2 receptor-specific cyt

1995-06-06

1996-12-24

Fitzgerald, David L.

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

Conjugated to proteinaceous toxin or fragment thereof

514 2, 514 8, 424 852, 4241341, 4241441, 4241541, 4241731, 4241821, 42419511, 42419711, A61K 3820, A61K 39395, A61K 4500

Patent

active

055871623

ABSTRACT:
Methods of inhibiting the rejection and prolonging the survival of an allograft in a mammal are provided. The methods involve administering to the mammal a cytotoxin-conjugated IL-2 receptor-specific substance during a proliferative burst of IL-2 receptor-bearing lymphocytes associated with the allograft whereby the lymphocytes undergoing the proliferative burst are selectively killed.

REFERENCES:
patent: 520226 (1885-05-01), Neville et al.
patent: 4359457 (1982-11-01), Neville et al.
patent: 4388309 (1983-06-01), Fabricius
patent: 4440747 (1984-04-01), Neville
patent: 4443427 (1984-04-01), Reinherz et al.
patent: 4489710 (1984-12-01), Spitler
patent: 4545985 (1985-10-01), Pastan
patent: 4550086 (1985-11-01), Reinherz et al.
patent: 4675382 (1987-06-01), Murphy
patent: 4677061 (1987-06-01), Rose et al.
patent: 4908433 (1990-03-01), Mertelsmann
patent: 4946674 (1990-08-01), von Eichborn et al.
patent: 5011684 (1991-04-01), Strom
patent: 5336489 (1994-08-01), Strom
patent: 5510105 (1996-04-01), Strom
Biosis Abs. No. 29034133.
Waldmann, "The Structure, Function, and Expression of Interleukin-2 Receptors on Normal and Malignant Lymphocytes," Science 232:727-732 (1986).
Olsnes, et al., Pharmacol. Ther. 15:355-381 (1981).
Sewell, et al., Arthrit. & Rheum. 36(9):1223-1233 (1993).
Gottlieb, et al., (Nature Medicine) 1(5):1442-1447 (1995).
Stenmark, et al., J. Cell Biol. 113(5):1025-1032 (1991).
Kirkman, et al., J. Exp. Med. 162(1):358-362 (1985).
Gaulton, et al., Clin. Immunol. Immunopathol. 36(1):18-29 (1985).
Federation Proceedings, vol. 44(4), 1681, Abstract No. 7430, Mar., 1985.
Clinical Research, vol. 33(2), 561A, Apr. 1985.
Federation Proceedings, 44(6), 1881, Abstract No. 8589, Mar. 1985.
Bellamy, et al., Clin.. Exp. Immunol. 61(2):248-256, Aug. 1985.
Howard, et al., Transplantation Proceedings, 13(1):473-474 (1981).
Uchiyama, et al., J. Immunol. 126(4):1393-1397 (1981).
Cantrell, et al., J. Exp. Med. 158:1895-1911 (1983).
Heidecke, et al., J. Immunol. 133(2):582-588 (1984).
Reem, et al., Science 225:429-430 (1984).
Cantrell, et al., Science 224:1312-1316 (1984).
Najarian, et al., Ann. Surg. 184:352-368 (1976).
Waldmann, Annu. Rev. Biochem. 58:875-911 (1989).
Brostoff et al., J. Immunol. 133(4):1938-1942 (1984).
Waldor et al., Science 227:415-417 (1985).
Takahashi et al. (1983) The Lancet pp. 1155-1158.
Williams et al. (1984) J. Immunol. 132(5), 2330.
Kirkman et al. (1983) Transplantation 36(6), 620.
Depper, et al. (1983) J. Immunol. 131(2), 690.
Cotner, et al. (1983) Journal of Experimental Medicine 157 461-472.
Knox, R., "Researchers find new way to stop organ rejection," Boston Globe, May 5, 1985, p. 20.
Kelley, V. E., et al., J. Immunol. 140:59-61 (1988).
Lorberboum-Galski, H., et al., Proc. Natl. Acad. Sci. USA 86:1008-12 (1989).
Kirkman et al., Transplantation 40(6):719-22 (1985).
Fahey, et al., Annals of Internal Med. 106:257-74 (1987).
Case, et al., PNSA USA 86:287-91 (1989).
Decker, et al., Ann. Int. Med. 101:810-24 (1984).
Powers, et al., Ann. Rev. Med. 36:533-44 (1985).
Prud'homme, et al., Diabetes 33:801-03 (1984).
Rossini, et al., Diabetes 33:543-47 91984).
Hofman et al., J. Immunol. 136:3239-45 (1986).
Fleischer et al., J. Neuroimmunol. 7:151-62 (1984).
Kronke et al., Blood 65(6):1416-1421 (1985).
Shimizu et al., Cell Structure and Function, 9, 1984, pp. 203-212.
Vallera et al., Science 222:512-515 (1983).
Strong et al., Blood 66(3):627-635 (1985).

Affiliated with

Also associated with

Rating

Treatment of allograft rejection with IL-2 receptor-specific cyt does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of allograft rejection with IL-2 receptor-specific cyt, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of allograft rejection with IL-2 receptor-specific cyt will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1177121